Abstract

Recent approaches in the treatment of cancer focus on involving the immune system to control the tumor growth. The administration of immunotherapies, like checkpoint inhibitors, has shown impressive results in the long term survival of patients. Cancer vaccines are being investigated as further tools to prime tumor-specific immunity. Biomaterials show potential as adjuvants in the formulation of vaccines, and biomimetic elements derived from the membrane of tumor cells may widen the range of antigens contained in the vaccine. Here, we show how mice presenting an aggressive melanoma tumor model treated twice with the complete nanovaccine formulation showed control on the tumor progression, while in a less aggressive model, the animals showed remission and control on the tumor progression, with a modification in the immunological profile of the tumor microenvironment. We also prove that co-administration of the nanovaccine together with a checkpoint inhibitor increases the efficacy of the treatment (87.5% of the animals responding, with 2 remissions) compared to the checkpoint inhibitor alone in the B16.OVA model. Our platform thereby shows potential applications as a cancer nanovaccine in combination with the standard clinical care treatment for melanoma cancers.
Original languageEnglish
JournalACS Nano
Volume13
Issue number6
Pages (from-to)6477-6490
Number of pages14
ISSN1936-0851
DOIs
Publication statusPublished - 17 May 2019
MoE publication typeA1 Journal article-refereed

Fields of Science

  • 317 Pharmacy
  • Nanotechnology
  • Cancer Vaccine
  • Immunotherapy
  • Biohybrid
  • Porous Silicon
  • Microfluidics
  • Melanoma
  • Immune checkpoint inhibitor

Cite this

@article{a8aadac7e5f3411abc77dd314006154e,
title = "Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor",
abstract = "Recent approaches in the treatment of cancer focus on involving the immune system to control the tumor growth. The administration of immunotherapies, like checkpoint inhibitors, has shown impressive results in the long term survival of patients. Cancer vaccines are being investigated as further tools to prime tumor-specific immunity. Biomaterials show potential as adjuvants in the formulation of vaccines, and biomimetic elements derived from the membrane of tumor cells may widen the range of antigens contained in the vaccine. Here, we show how mice presenting an aggressive melanoma tumor model treated twice with the complete nanovaccine formulation showed control on the tumor progression, while in a less aggressive model, the animals showed remission and control on the tumor progression, with a modification in the immunological profile of the tumor microenvironment. We also prove that co-administration of the nanovaccine together with a checkpoint inhibitor increases the efficacy of the treatment (87.5{\%} of the animals responding, with 2 remissions) compared to the checkpoint inhibitor alone in the B16.OVA model. Our platform thereby shows potential applications as a cancer nanovaccine in combination with the standard clinical care treatment for melanoma cancers.",
keywords = "317 Pharmacy, Nanotechnology, Cancer Vaccine, Immunotherapy, Biohybrid, Porous Silicon, Microfluidics, Melanoma, Immune checkpoint inhibitor",
author = "Flavia Fontana and Manlio Fusciello and Christianne Groeneveldt and Cristian Capasso and Jacopo Chiaro and Sara Feola and Zehua Liu and Ermei M{\"a}kil{\"a} and Jarno Salonen and Jouni Hirvonen and Vincenzo Cerullo and Santos, {H{\'e}lder A.}",
year = "2019",
month = "5",
day = "17",
doi = "10.1021/acsnano.8b09613",
language = "English",
volume = "13",
pages = "6477--6490",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "6",

}

Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor. / Fontana, Flavia; Fusciello, Manlio; Groeneveldt, Christianne ; Capasso, Cristian; Chiaro, Jacopo; Feola, Sara; Liu, Zehua; Mäkilä, Ermei; Salonen, Jarno; Hirvonen, Jouni; Cerullo, Vincenzo; Santos, Hélder A.

In: ACS Nano, Vol. 13, No. 6, 17.05.2019, p. 6477-6490.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor

AU - Fontana, Flavia

AU - Fusciello, Manlio

AU - Groeneveldt, Christianne

AU - Capasso, Cristian

AU - Chiaro, Jacopo

AU - Feola, Sara

AU - Liu, Zehua

AU - Mäkilä, Ermei

AU - Salonen, Jarno

AU - Hirvonen, Jouni

AU - Cerullo, Vincenzo

AU - Santos, Hélder A.

PY - 2019/5/17

Y1 - 2019/5/17

N2 - Recent approaches in the treatment of cancer focus on involving the immune system to control the tumor growth. The administration of immunotherapies, like checkpoint inhibitors, has shown impressive results in the long term survival of patients. Cancer vaccines are being investigated as further tools to prime tumor-specific immunity. Biomaterials show potential as adjuvants in the formulation of vaccines, and biomimetic elements derived from the membrane of tumor cells may widen the range of antigens contained in the vaccine. Here, we show how mice presenting an aggressive melanoma tumor model treated twice with the complete nanovaccine formulation showed control on the tumor progression, while in a less aggressive model, the animals showed remission and control on the tumor progression, with a modification in the immunological profile of the tumor microenvironment. We also prove that co-administration of the nanovaccine together with a checkpoint inhibitor increases the efficacy of the treatment (87.5% of the animals responding, with 2 remissions) compared to the checkpoint inhibitor alone in the B16.OVA model. Our platform thereby shows potential applications as a cancer nanovaccine in combination with the standard clinical care treatment for melanoma cancers.

AB - Recent approaches in the treatment of cancer focus on involving the immune system to control the tumor growth. The administration of immunotherapies, like checkpoint inhibitors, has shown impressive results in the long term survival of patients. Cancer vaccines are being investigated as further tools to prime tumor-specific immunity. Biomaterials show potential as adjuvants in the formulation of vaccines, and biomimetic elements derived from the membrane of tumor cells may widen the range of antigens contained in the vaccine. Here, we show how mice presenting an aggressive melanoma tumor model treated twice with the complete nanovaccine formulation showed control on the tumor progression, while in a less aggressive model, the animals showed remission and control on the tumor progression, with a modification in the immunological profile of the tumor microenvironment. We also prove that co-administration of the nanovaccine together with a checkpoint inhibitor increases the efficacy of the treatment (87.5% of the animals responding, with 2 remissions) compared to the checkpoint inhibitor alone in the B16.OVA model. Our platform thereby shows potential applications as a cancer nanovaccine in combination with the standard clinical care treatment for melanoma cancers.

KW - 317 Pharmacy

KW - Nanotechnology

KW - Cancer Vaccine

KW - Immunotherapy

KW - Biohybrid

KW - Porous Silicon

KW - Microfluidics

KW - Melanoma

KW - Immune checkpoint inhibitor

U2 - 10.1021/acsnano.8b09613

DO - 10.1021/acsnano.8b09613

M3 - Article

VL - 13

SP - 6477

EP - 6490

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 6

ER -